Next Generation Antibody Therapeutics: From Discovery to Patient

摘要 请求支持Keystone研讨会会议，题为下一代抗体治疗： 从发现到病人，由帕梅拉·霍兰德和詹姆斯·威尔斯博士组织。举行这次会议 2023年2月19日至22日在加拿大不列颠哥伦比亚省班夫举行。 治疗性抗体已成为获得FDA批准的主要类别的新药， 医药市场上用于治疗各种人类疾病，包括癌症， 自身免疫性疾病和传染病。在过去的30年里，重大的技术进步促进了 单克隆抗体疗法的发现和发展，以及新的策略不断涌现 来提高他们的临床潜力虽然取得了重大进展，但新的机会和 在这一迅速发展的领域，挑战继续演变。抗体技术的多项进展将扩大 抗体属性已经转化为在多个治疗领域中的改进的临床活性。但他们 还揭示了在目标验证、作用方法、蛋白质设计、开发 时间和管理抗体制造的增加的成本。本次会议将提供一个多样化的 该计划由学术和行业科学家组成，旨在应对挑战和机遇 与抗体药物发现和开发相关。此外，它将包括侧重于以下方面的会议： 目标识别和新的发现平台，以及蛋白质工程的进展，以改善 功能特性和新的抗体形式和递送方法。也会有一些主题， 提供肿瘤学、感染性疾病和 自身免疫/炎症。总的来说，该计划将为调查人员提供一个全面的视角， 从实验室到床边的抗体治疗开发，将突出尖端技术和 广泛的科学家感兴趣的临床进展。最后，本次会议将与 另一个关于癌症免疫治疗的多特异性免疫细胞参与者的Keystone研讨会会议。这 将使与会者在这两个会议的机会，网络和发展新的合作，通过 分享会议和用餐。会议将提供一个刺激的环境，学生，博士后 初级研究人员可以与该领域最优秀的人才展示和讨论他们的研究。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Next Generation Antibody Therapeutics: From Discovery to Patient, organized by Drs. Pamela Holland and James Wells. The conference will be held in Banff, British Columbia, Canada, from February 19-22, 2023. Therapeutic antibodies have become the predominant class of new drugs gaining FDA approval and are the best-selling drugs in the pharmaceutical market for treating various human diseases, including cancer, autoimmune, and infectious diseases. Over the past 30 years, major technological advances have facilitated the discovery and development of monoclonal antibody therapies, and new strategies are continually emerging to enhance their clinical potential. Though substantial progress has been made, new opportunities and challenges continue to evolve in this rapidly moving field. Multiple advances in antibody technology to expand antibody attributes have already translated into improved clinical activity in multiple therapeutic areas. Yet they also unveil major challenges with respect to target validation, method of action, protein design, development time, and managing increasing costs of antibody manufacturing. This conference will provide a diverse program comprised of academic and industry scientists that addresses the challenges and opportunities relevant to antibody drug discovery and development. Furthermore, it will include sessions which focus on target identification and novel discovery platforms, as well as advances in protein engineering to improve functional properties and new antibody modalities and delivery methods. There will also be topics that will provide an overview of emerging clinical therapeutics in oncology, infectious disease and autoimmunity/inflammation. Overall, this program will offer investigators a perspective on the full spectrum of antibody therapeutic development from bench to bedside and will highlight cutting edge technological and clinical advancements of interest to a broad spectrum of scientists. Finally, this conference is being paired with another Keystone Symposia meeting on Multispecific Immune Cell Engagers for Cancer Immunotherapy. This will allow participants at both conferences the chance to network and develop new collaborations through shared sessions and meals. The conference will provide a stimulating environment where students, postdocs and junior investigators can present and discuss their research with the best minds in the field.